| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RAD51 |
| Uniprot No | Q06609 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-339aa |
| 氨基酸序列 | GSHMAMQMQL EANADTSVEE ESFGPQPISR LEQCGINAND VKKLEEAGFH TVEAVAYAPK KELINIKGIS EAKADKILAE AAKLVPMGFT TATEFHQRRS EIIQITTGSK ELDKLLQGGI ETGSITEMFG EFRTGKTQIC HTLAVTCQLP IDRGGGEGKA MYIDTEGTFR PERLLAVAER YGLSGSDVLD NVAYARAFNT DHQTQLLYQA SAMMVESRYA LLIVDSATAL YRTDYSGRGE LSARQMHLAR FLRMLLRLAD EFGVAVVITN QVVAQVDGAA MFAADPKKPI GGNIIAHAST TRLYLRKGRG ETRICKIYDS PCLPEAEAMF AINADGVGDA KD |
| 预测分子量 | 37 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RAD51重组蛋白的3-4篇关键文献及其摘要概述：
---
1. **文献名称**：*Mechanisms and regulation of mitotic recombination in Saccharomyces cerevisiae*
**作者**：Symington, L. S., Rothstein, R., & Lisby, M.
**摘要**：综述了RAD51蛋白在真核生物同源重组修复(HR)中的核心作用，包括其与单链DNA结合形成核蛋白丝的机制，以及与其他辅助因子(如BRCA2)协同修复DNA双链断裂(DSBs)的过程。
2. **文献名称**：*Homologous recombination and its role in cancer genesis and treatment*
**作者**：Jasin, M., & Rothstein, R.
**摘要**：探讨了RAD51介导的同源重组在维持基因组稳定性中的重要性，指出RAD51功能缺陷可能导致染色体异常和癌症发生，同时强调了其在化疗耐药性中的潜在影响。
3. **文献名称**：*Human RAD51 recombination: A key player in DNA repair and genome maintenance*
**作者**：Kowalczykowski, S. C.
**摘要**：通过体外实验揭示了RAD51在DNA链交换和重组中间体形成中的动态行为，并分析了其与辅助蛋白(如RAD54)的协同作用机制。
4. **文献名称**：*Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy*
**作者**：Ashworth, A., & D'Andrea, A. D.
**摘要**：讨论了BRCA1/2突变肿瘤细胞依赖RAD51介导的修复通路的合成致死效应，为PARP抑制剂等靶向疗法的开发提供了理论依据。
---
这些文献涵盖了RAD51在DNA修复、癌症发生及治疗中的核心机制和临床应用。
RAD51 is a crucial eukaryotic recombinase that plays a central role in homologous recombination (HR), a high-fidelity DNA repair pathway essential for maintaining genomic stability. It is evolutionarily conserved and functionally analogous to bacterial RecA. RAD51 facilitates the repair of DNA double-strand breaks (DSBs) and stalled replication forks by promoting strand pairing and exchange between homologous DNA sequences. This process ensures accurate repair while minimizing mutagenic outcomes, distinguishing HR from error-prone repair mechanisms.
During HR, RAD51 assembles into helical filaments on single-stranded DNA (ssDNA) regions generated by resection of DSBs. These nucleoprotein filaments mediate homology search and strand invasion into undamaged sister chromatids or homologous chromosomes, forming a displacement loop (D-loop) that serves as a template for accurate repair. RAD51 activity is tightly regulated by various accessory proteins, including BRCA2. RAD52. and RAD51 paralogs, which facilitate filament formation, stability, and disassembly. Post-translational modifications such as phosphorylation and ubiquitination further modulate its function.
Dysregulation of RAD51 is linked to genome instability, cancer predisposition, and therapy resistance. Germline mutations in BRCA1/2. which interact directly with RAD51. are associated with hereditary breast and ovarian cancers. Paradoxically, while HR defects in cancers can sensitize cells to DNA-damaging agents, RAD51 overexpression in tumors often confers resistance to radiotherapy and chemotherapy by enhancing repair capacity. This dual role makes RAD51 a potential therapeutic target; inhibitors are being explored to sensitize HR-proficient cancers or exploit synthetic lethality in combination with PARP inhibitors.
Beyond repair, RAD51 participates in meiotic recombination and telomere maintenance. Its expression levels are being investigated as predictive biomarkers for cancer treatment response. Structural studies of RAD51-DNA complexes continue to inform the development of small-molecule modulators, highlighting its significance in both basic biology and translational applications.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
